Nephrotoxicity of vancomycin in patients with methicillin‐resistant <i>Staphylococcus aureus</i> bacteraemia

Shen, Wan Chen; Chiang, Yi Chun; Chen, Hsiang-Yin; Chen, Tso Hsiao; Yu, Fenglei; Tang, Chao Hsiun; Sue, Yuh Mou

doi:10.1111/j.1440-1797.2011.01488.x

Cited by 21 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for antibacterial agents, piperacillin‐tazobactam and vancomycin were frequently reported to be associated with AKI. Piperacillin‐tazobactam alone has rarely been reported to be associated with AKI, whereas the association of vancomycin alone with AKI has been reported . However, vancomycin in combination with piperacillin‐tazobactam was associated with a greater risk of AKI than vancomycin with or without β‐lactam .…”

Section: Discussionmentioning

confidence: 99%

“…AKI, acute kidney injury DRUG reported to be associated with AKI, 21 whereas the association of vancomycin alone with AKI has been reported. 22,23 However, vancomycin in combination with piperacillin-tazobactam was associated with a greater risk of AKI than vancomycin with or without β-lactam. 24 Clinically, the combination of piperacillin-tazobactam and vancomycin is often used, and so it is noteworthy that their combined use increased the risk.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Nephrotoxicity was defined as a ≥50% increase of the serum creatinine level from baseline, defined as before starting this combined regimen. Patients with acute renal failure were classified using the RIFLE criteria (Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and End‐stage kidney disease), which are highly sensitive for diagnosis of vancomycin‐associated acute renal failure , and have a good prognostic value .…”

Section: Methodsmentioning

confidence: 99%

Continuous high-dose vancomycin combination therapy for methicillin-resistant staphylococcal prosthetic hip infection: a prospective cohort study

Dubée

Zeller

Lhotellier³

et al. 2013

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Few data are available on treatment and outcome of methicillin-resistant (MR) staphylococcal prosthetic joint infections. Vancomycin remains the treatment of choice for these infections, but its efficacy and safety in bone-and-joint infections are insufficiently documented. We conducted a prospective cohort study on 60 patients treated between November 2002 and December 2008 for chronic MR staphylococcal (44 S. epidermidis, nine other coagulase-negative Staphylococcus and seven S. aureus) prosthetic hip infections (PHIs). Twenty-two patients had previously undergone surgery for their PHI and 21 had previously received antibiotics. All patients had surgery (exchange arthroplasty for 58 patients, resection arthroplasty for two) and received an antibiotic regimen combining high-dose continuous intravenous vancomycin infusion (target serum concentration 30-40 mg/L) with another antibiotic for 6 weeks, followed by an additional 6 weeks of oral intake. Two years after surgery, infection was considered cured in 41 (68%) patients and only two relapses occurred after one-stage exchange arthroplasty. Nineteen (32%) patients experienced nephrotoxicity that was generally mild (RIFLE class R for 14 patients, class I for four patients and class F for one patient) and most often reversible. Continuous high-dose intravenous vancomycin combination therapy is an effective, feasible and reasonably safe treatment of chronic MR staphylococcal PHI.

show abstract

“…This study is the first large scale investigation of VA-AKI in Hong Kong. In previous studies, the incidence of VA-AKI in Chinese varied from 2.4 to 45% [9,[13][14][15][16] (Additional file 1: Table S1). The difference of estimated incidence is due to different populations, sample sizes, inclusion criteria and AKI definition.…”

Section: Discussionmentioning

confidence: 99%

Vancomycin-associated acute kidney injury in Hong Kong in 2012–2016

et al. 2020

View full text Add to dashboard Cite

Background:To study the incidence of vancomycin-associated acute kidney injury (VA-AKI) in Hong Kong and identify risk factors for VA-AKI. Method: Patients with vancomycin prescription and blood level measurement in 2012-2016 were identified using the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System. Acute kidney injury was defined using KDIGO criteria. Patients without creatinine measurements, steady-state trough vancomycin level or who had vancomycin treatment < 3 days were excluded. Results were analyzed using SPSS version 22.0. Logistic regression was used to identify the predictors for VA-AKI. Odds ratio and 95% confidence interval were estimated. Results: One thousand four hundred fifty patients were identified as VA-AKI from 12,758 records in Hong Kong in 2012-2016. The incidence was respectively 10.6, 10.9, 11.3, 12.2, 11.2% from 2012 to 2016. The incidence of VA-AKI was 16.3, 12.2, 11.3 and 6.2% in patients aged 1-12, 12-60, elderly aged > 60 and newborn and infants, respectively. Baseline creatinine, serum trough vancomycin level, systematic disease history including respiratory failure, hypertension, congestive heart failure, chronic renal failure, anemia and type II diabetes, and concomitant diuretics, piperacillin-tazobactam (PTZ) and meropenem prescription were significantly higher in VA-AKI patients older than 12 years. Logistic regression showed that older age group, higher baseline creatinine, serum trough vancomycin level, respiratory failure, chronic renal failure and congestive heart failure, concomitant diuretics, PTZ and meropenem prescription, and longer hospital stay were all associated with increased risk of VA-AKI. Conclusion: The incidence of VA-AKI in Hong Kong is low but shows no decline. Patients with higher baseline creatinine, multi-organ diseases and multiple drugs administration should have their vancomycin level monitored to decrease the risk of VA-AKI.

show abstract

Nephrotoxicity of vancomycin in patients with methicillin‐resistant Staphylococcus aureus bacteraemia

Abstract: The study data suggest that vancomycin is associated with a higher likelihood of nephrotoxicity using the RIFLE classification.

Cited by 21 publications

References 36 publications

Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach

Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach

Continuous high-dose vancomycin combination therapy for methicillin-resistant staphylococcal prosthetic hip infection: a prospective cohort study

Vancomycin-associated acute kidney injury in Hong Kong in 2012–2016

Contact Info

Product

Resources

About